Novel cancer treatment and the cardiovascular risk : What should cardiologists know?

[Novel cancer treatment and the cardiovascular risk : What should cardiologists know?] Herz. 2020 Feb 20;: Authors: Totzeck M, Rassaf T Abstract Cardiotoxic side effects can significantly limit the quality of life and survival of tumor patients under treatment. Acute and chronic effects include hypertension, venous and arterial thromboembolic events, acute and chronic coronary syndromes, heart failure and arrhythmias. Patients with previous cardiovascular diseases are often more frequently affected by side effects. The triggers are not only irradiation and conventional chemotherapy but increasingly also newer forms of cancer treatment. These include targeted therapy and immune checkpoint inhibitors (ICI). The goals of oncological cardiology are the prevention, timely diagnosis and treatment of these side effects in order to optimize patient outcomes. PMID: 32077982 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research

Related Links:

ConclusionsA high incidence of CV events, with no apparent correlation with CV comorbidities or risk factors, was observed. Prompt identification and treatment of CV events allowed most pts to complete the treatment with FP.Clinical trial identificationNCT02665312.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureM. Aglietta: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewDue to advancements in oncologic treatment strategies and techniques, the number of survivors who have undergone hematopoetic stem cell transplant (HCT) continues to increase in the United States; this number is projected to reach 502,000 by the year 2030. There is significant interest within the field of cardio-oncology to identify cardiotoxicity and cardiovascular disease in the HCT population. Epidemiologic studies analyzing both short- and long-term cardiovascular effects, risk stratification modeling, cardioprotective strategies, and expert consensus documents for cardiotoxicity surveillance r...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Publication date: Available online 24 April 2018Source: Pharmacology &TherapeuticsAuthor(s): Joachim Alexandre, Javid J. Molsehi, Kevin R. Bersell, Christian Funck-Brentano, Dan M. Roden, Joe-Elie SalemAbstractSignificant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases. Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy. Much attention has focused on he...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Authors: Hoog J, Achenbach S Abstract The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardi...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
Publication date: Available online 5 September 2016 Source:Pharmacology & Therapeutics Author(s): Tarek Magdy, Brian T. Burmeister, Paul W. Burridge The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development the field cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of arrhythmias. Of these cardiotoxic drugs, those resulting in clinic...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Conclusions The results of this study suggest trametinib has no significant effect on QT prolongation at supratherapeutic exposure.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 2 March 2016 Source:Canadian Journal of Cardiology Author(s): Paul C. Nathan, Eitan Amir, Husam Abdel-Qadir Over 80% of children and 60% of adults with cancer will become long-term survivors, emphasizing the importance of late effects of cancer therapy. Cardiotoxicity due to chemotherapy and radiation is a frequent cause of serious morbidity and premature mortality in survivors. Anthracyclines, a core component of many treatment regimens, have been implicated as a principal cause of irreversible cardiomyopathy. Approximately 60% of anthracycline-treated children will develop echocard...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled. If loading fails, click here to try again Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. There is no time limit for this mock test. Start Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 4. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rate...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology MCQ DM / DNB Cardiology Entrance Featured Source Type: blogs
Publication date: Available online 28 December 2015 Source:Canadian Journal of Cardiology Author(s): Alan C. Cameron, Rhian M. Touyz, Ninian N. Lang Development of new anticancer drugs has resulted in improved mortality rates and 5-year survival rates in patients with cancer. However, many of the modern chemotherapies are associated with cardiovascular toxicities that increase cardiovascular risk in cancer patients, including hypertension, thrombosis, heart failure, cardiomyopathy and arrhythmias. These limitations restrict treatment options and may impact negatively on the management of cancer. The cardiotoxic effect...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
This study will evaluate the cardiac safety of two anthracycline-based neoadjuvant regimens in combination with P+T. Following surgery, all pts will receive adjuvant P+T. Trial design: In this non-randomized, open-label, phase II study, two parallel cohorts of pts receive different P-based neoadjuvant treatment regimens. In Cohort A, pts receive four 2-weekly cycles of ddAC, followed by 12 doses of weekly Ptx, plus four 3-weekly (q3w) cycles of P+T from the start of Ptx. In Cohort B, pts receive four q3w cycles of 5-fluorouracil, epirubicin, and cyclophosphamide, followed by four q3w cycles of D, plus four q3w cycles of P+...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Ongoing Clinical Trials Source Type: research
More News: Arrhythmia | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Heart | Heart Failure | Hypertension